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Tissue inhibitor ofmetalloproteinases-3 (TIMP-3) is a central
inhibitor of matrix-degrading and sheddase families of metallo-
proteinases. Extracellular levels of the inhibitor are regulated by
the balance between its retention on the extracellular matrix
and its endocytic clearance by the scavenger receptor low den-
sity lipoprotein receptor-related protein 1 (LRP1). Here, we
used molecular modeling to predict TIMP-3 residues poten-
tially involved in binding to LRP1 based on the proposed LRP1
binding motif of 2 lysine residues separated by about 21 Å and
mutated the candidate lysine residues to alanine individually
and in pairs. Of the 22 mutants generated, 13 displayed a
reduced rate of uptake by HTB94 chondrosarcoma cells. The
twomutants (TIMP-3K26A/K45AandK42A/K110A)with low-
est rates of uptake were further evaluated and found to display
reduced binding to LRP1 and unaltered inhibitory activity
against prototypic metalloproteinases. TIMP-3 K26A/K45A
retained higher affinity for sulfated glycosaminoglycans than
K42A/K110A and exhibited increased affinity for ADAMTS-5
in the presence of heparin. Both mutants inhibited metallopro-
teinase-mediated degradation of cartilage at lower concentra-
tions and for longer than wild-type TIMP-3, indicating that
their increased half-lives improved their ability to protect carti-
lage. These mutants may be useful in treating connective tissue
diseases associated with increased metalloproteinase activity.
Tissue inhibitor of metalloproteinases-3 (TIMP-3)2 is an
endogenous inhibitor of metalloproteinase catalytic activity
and hence an important regulator of connective tissue turnover
by these enzymes (1–3). TIMP-3 is unique among the four
mammalian TIMPs in that it can inhibit not only matrix met-
alloproteinases (MMPs), but also the related adamalysins (a dis-
integrin and metalloproteinase (ADAMs)) and adamalysins
with thrombospondin motifs (ADAMTSs).
Various pathophysiological states are associated with dis-
rupted extracellular matrix (ECM) turnover. For example,
osteoarthritis is characterized by degradation of type II collagen
and aggrecan by collagenolytic MMPs and aggrecan-degrading
ADAMTSs, respectively. Timp3-null mice show increased col-
lagenase and aggrecanase activity in cartilage and increased
spontaneous osteoarthritis with age (4). TIMP-3 levels are
reduced in human osteoarthritic cartilage (5). Treatment with
recombinant TIMP-3 has been shown to block cartilage degra-
dation in vitro (6) and in in vivo models of osteoarthritis (7),
further illustrating the chondroprotective activity of TIMP-3.
The half-life of TIMP-3 in tissue is positively regulated by its
binding to the ECM (8, 9) and negatively regulated by its endo-
cytosis and subsequent lysosomal degradation via low density
lipoprotein receptor-related protein 1 (LRP1) (10, 11).We pos-
tulated that a mutant of TIMP-3 with reduced affinity for LRP1
would have a longer half-life in tissue and an increased ability to
block metalloproteinase activities compared with wild-type
TIMP-3.
Previous mutagenesis (12–14), crystallography (15), and
NMR (16) studies on LRP1 ligands have identified a receptor
bindingmotif comprising 2 surface-located lysine residues sep-
arated by 21 Å. These lysine residues interact with acidic pock-
ets on two sequential complementary repeats of LRP1 (15).
Receptor-associated protein (RAP) is a folding chaperone of the
LRP family and has served as a prototypic ligand in many stud-
ies investigating LRP-ligand interactions. RAP Lys-256 and
Lys-270 are thought to be primarily responsible for binding to
LRP1, because theRAPmutantK256A/K270A showsnegligible
LRP1 binding and endocytosis (13, 14). Other LRP1 ligands,
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including activated 2-macroglobulin (17), factor VIII (18, 19),
and the serpins plasminogen activator inhibitor-1 (PAI-1) (20,
21), and nexin-1 (21), have also been shown to utilize lysine
residues for LRP1 binding, suggesting that ligands interact with
LRP1 though a common mechanism.
To engineer LRP1-resistantmutants of TIMP-3, we analyzed
a model of the three-dimensional structure of full-length
TIMP-3 and identified pairs of lysine residues potentially sep-
arated by 21 Å. These lysine residues were mutated to alanine
singly and in pairs, and the endocytosis resistance, LRP1 bind-
ing, and chondroprotective ability of the mutants were evalu-
ated. Two of the engineeredmutants, TIMP-3 K26A/K45A and
K42A/K110A, exhibited substantial endocytosis resistance and
protected cartilage better than wild-type TIMP-3. We thus
show that targeting the TIMP-3 endocytosis pathway is a
potential strategy for inhibiting excessmetalloproteinase activ-
ity in pathological settings.
Results
Design of TIMP-3 Mutants—Because no crystal structure of
full-length TIMP-3 is available, we constructed a homology
model of the TIMP-3 structure using the available TIMP-2
(Protein Data Bank code 1BR9) (22) structure. We then com-
pared the N-terminal domain of TIMP-3 in our model with the
available crystal structure of the N-terminal domain of TIMP-3
in complex with ADAM17 (Protein Data Bank code 3CKI) (23)
and observed good agreement between the two structures. The
most C-terminal lysine residue (Lys-180) is unresolved in the
model. The remaining 16 lysine residues of TIMP-3 are pre-
dicted to be located on the surface of the protein.Wemeasured
the distance between -carbon residues of pairs of lysine resi-
dues and identified 10 pairs of lysine residues predicted to be
separated by 21 5 Å. (Fig. 1). With the exception of Lys-157,
all lysine residues identified were located on the N-terminal
inhibitory domain of TIMP-3. Using site-directedmutagenesis,
we generated 10 mutants of TIMP-3 in which both lysine resi-
dues of the potential LRP1-binding dilysinemotif weremutated
to alanine as well as 12 mutants in which the individual lysine
residues identified were singly mutated to alanine (Table 1). A
FLAG tag was included at the C terminus of all mutants for
detection and purification, as described previously for wild-
type TIMP-3 (24).
Screening ofMutants—We carried out an initial screen of the
mutants using immunoblotting to evaluate their rate of disap-
pearance from the medium of HTB94 chondrosarcoma cells.
These cells secrete a minimal amount of TIMP-3-binding
ECM, and disappearance of TIMP-3 from the medium reflects
its endocytosis into cells via LRP1 (11).
HEK-293-EBNA cells were transiently transfected with the
mutants and conditioned medium dialyzed against TBS. We
confirmed that wild-type TIMP-3 in such dialyzed crude con-
ditioned medium was endocytosed by HTB94 with indistin-
FIGURE1. Identificationofpotential LRP1-binding residues inTIMP-3.Amodel of TIMP-3was generatedusing the available crystal structure of TIMP-2. The
positionof Lys-180was unresolved in themodel, but the remaining 16 lysine residues of TIMP-3were all predicted tobe locatedon the surface of themolecule.
Lysine residues located on the N-terminal domain of TIMP-3 are indicated in purple, and those on the C-terminal domain are shown in blue. The distance
between-carbon residues of pairs of lysine residueswasmeasured, and 10pairs of lysine residues (listed on the right) were predicted to be separatedby 21
5 Å. This figure was made with PyMOL.
TABLE 1
Candidate LRP1-resistant mutants of TIMP-3 generated
Using amodel of TIMP-3, 10 pairs of Lys residues were predicted to be separated by
21 5 Å on the surface of TIMP-3, and 10 double Lys3 Ala mutants were gener-
ated. The 12 constituent single Lys3 Ala mutants generated are also listed.
Mutant
Distance between lysine
-carbon atoms
Å
Double Lys3 Ala mutants
of TIMP-3 generated
K22A/K110A 16.7
K22A/K157A 22.3
K26A/K45A 19.4
K27A/K45A 23.9
K30A/K52A 23.0
K30A/K76A 21.2
K42A/K110A 20.6
K42A/K157A 25.9
K45A/K89A 15.6
K71A/K157A 24.6
Single Lys3 Ala mutants
of TIMP-3 generated
K22A
K26A
K27A
K30A
K42A
K45A
K52A
K71A
K76A
K89A
K110A
K157A
TIMP-3Mutants Resistant to LRP1 Have Increased Half-life
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guishable kinetics from purified recombinant TIMP-3, validat-
ing this method as a screening tool. Clearance was inhibited by
RAP (Fig. 2, A and B), confirming our previous findings that
TIMP-3 is endocytosed in an LRP1-dependentmanner (10, 11).
Wild-type TIMP-3 was lost from themediumwith a half-life
of 3.6 0.3 h (Fig. 2A). TIMP-3K42A,K71A, andK157Aexhib-
ited significantly increased half-lives of 8.8  1.6, 12.9  0.4,
and 7.8  2.5 h, respectively (Fig. 2C). The remainder of the
single mutants showed no statistically significant change in
half-life, and 75% of all of the single mutants were lost from
the medium within 24 h.
We then analyzed the half-lives of TIMP-3mutants in which
both lysine residues of the potential LRP1-binding dilysine
motif were mutated to alanine. All of the double mutants
remained in the medium for markedly longer than the single
lysine mutants (Fig. 3). More than 50% of each remained in the
medium after 24 h, so half-lives could not be calculated, and we
compared the mutants based on the percentage remaining in
the medium at 24 h. TIMP-3 K42A/K110A and K26A/K45A
stayed in the medium at the highest concentration, with 92 
3% and 69  6% of these mutants remaining in the medium
after 24 h, respectively. Thesemutants were purified for further
characterization.
Purification of TIMP-3 K26A/K45A and K42A/K110A—
C-terminally FLAG-tagged TIMP-3 mutants were purified by
FLAG affinity chromatography as described previously for
wild-type TIMP-3 (24). K26A/K45A and K42A/K110A were
purified with lower yields (96 and 110g per liter, respectively)
thanwild-typeTIMP-3 (288g/liter). The remaining 8TIMP-3
double lysine mutants had yields of 20 g/liter. We con-
firmed that K26A/K45A and K42A/K110A retained the same
degree of endocytosis resistance as observed previously using
crude conditioned media. No cell toxicity was observed after
incubation of HTB94 with purified wild-type or mutant
TIMP-3 (50 or 100 nM) for 24 h (Fig. 3D).
Confocal Microscopy Imaging of Endocytosis—We added
purified wild-type TIMP-3 to HTB94 cells and observed co-lo-
calization of the protein with early endosomal antigen 1 (EEA1)
in endosomal vesicles (Fig. 4). Preincubation of cells with RAP
ablated this co-localization, confirming that TIMP-3 endocyto-
sis is LRP1-dependent. K26A/K45AandK42A/K110Awere not
visible within cells and did not co-localize with EEA1, confirm-
ing that they are not endocytosed.
Uptake by LRP1-null Cells—We compared uptake of wild-
type and mutant TIMP-3 by LRP-1 wild-type and null cells to
evaluate whether the altered uptake of the mutants was depen-
dent on LRP1. In LRP1 wild-type PEA10 cells, TIMP-3 was
rapidly taken up from the medium with a half-life of 1.9 h,
whereas K26A/K45A and K42A/K110A remained in the
medium (Fig. 5A). Conversely, all three proteins remained
at the same level in the medium of LRP1-null PEA13 cells
(Fig. 5B).
Binding to LRP1—Binding of themutants to full-length LRP1
was evaluated by ELISA. Wild-type TIMP-3 bound efficiently
to LRP1, whereas K26A/K45A bound with markedly reduced
affinity, and K42A/K110A displayedminimal binding (Fig. 6A).
Binding to Sulfated Glycosaminoglycans—Wild-type TIMP-3
had KD values of 3.7  0.24 and 5.1  0.3 nM for heparin and
heparan sulfate, respectively (Fig. 6, B and C). TIMP-3 K26A/
K45A displayed similar affinity, with KD values of 5.5 0.4 and
5.5  0.5 nM for heparin and heparan sulfate, respectively.
TIMP-3 K42A/K110A displayed 5-fold lower affinity, with KD
values of 27.4 5.3 and 25.4 2.8 nM for heparin and heparan
sulfate, respectively.
FIGURE 2.Mutation of single lysine residues increases half-life of TIMP-3
in themediumofHTB94chondrosarcomacells.A, HTB94 chondrosarcoma
cells were incubated (0–24 h)with 1 nM FLAG-taggedwild-type TIMP-3 (black
circle), TIMP-3 preincubated with 1 M RAP (white circle), or TIMP-3 mutant
K26A (red circle), K42A (blue square), or K45A (green triangle) in DMEM with
0.1% FCS. Media were concentrated by TCA precipitation and analyzed by
immunoblotting with anti-FLAG M2 antibody and densitometry using Pho-
retix 1D software. The loss of each mutant from the medium was calculated
relative to its pixel volume at t 0 h (defined as 100%). Immunoblots show a
representative experiment, and graphs show analysis of three technical rep-
licates (mean S.D. (error bars)). B, HTB94 chondrosarcoma cells were incu-
bated (0–24 h) with FLAG-tagged wild-type TIMP-3 (black circle), TIMP-3 pre-
incubated with 1 M RAP (white circle), or TIMP-3 mutant K71A (red circle),
TIMP-3 K110A (blue square), or K157A (green triangle) in DMEMwith 0.1% FCS.
Media were concentrated and analyzed as in A. Immunoblots show a repre-
sentative experiment, and graphs show analysis of three technical replicates
(mean  S.D.). C, half-lives of wild-type TIMP-3 and its mutants were calcu-
lated from A and B. Wild-type TIMP-3 had a half-life of 3.6  0.3 h. TIMP-3
mutants K42A, K71A, andK157A exhibited significantly increasedhalf-lives of
8.8 1.6, 12.9 0.4, and 7.8 2.5 h, respectively (**, p 0.01; ***, p 0.001).
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Characterization of Mutant Affinity for Prototypic Metal-
loproteinases—We compared the inhibition kinetics of the
K26A/K45A and K42A/K110A mutants with the wild-type
inhibitor. As shown in Table 2 (mean S.D., n 3–5), Ki(app)
values for wild-type TIMP-3 were in agreement with previous
findings (24–26), and TIMP-3 K26A/K45A and K42A/K110A
both displayed unaltered affinities for the catalytic domains of
MMP-1, MMP-2, and MMP-3, as well as ADAMTS-4 lacking
the C-terminal spacer domain, ADAMTS-5 lacking the C-ter-
minal thrombospondin domain, and the ectodomain of
ADAM17. LRP1 shedding, which is primarily caused by metal-
loproteinases, was also unaltered by the mutants (not shown).
Affinity for ADAMTS-5 in the Presence of Heparin—We have
previously shown that sulfated glycosaminoglycans, such as
heparin and heparan sulfate, increase affinity between wild-
type TIMP-3 and glycosaminoglyan-binding enzymes, such as
ADAMTS-5, bymediating formation of high affinity trimolecu-
lar complexes (27). As shown in Fig. 6D (representative exper-
iment) and Table 2 (mean S.D., n 3–5), heparin increased
TIMP-3 affinity for ADAMTS-5 from a Ki(app) value of 1.27
0.46 nM to a value too low to be calculated. Heparin similarly
increased K26A/K45A affinity for ADAMTS-5 from a Ki(app)
value of 0.95  0.55 nM to a value too low to be calculated. In
contrast, affinity of K42A/K110A for ADAMTS-5 was not
affected by heparin, with Ki(app) values of 1.12  0.94 and
1.20  0.42 nM in the absence and presence of heparin,
respectively.
Inhibition of Cartilage Degradation—The ability of the
mutants to inhibit IL-1-stimulated aggrecan degradation in
porcine cartilage explants was evaluated. In a 48-h assay, glyco-
saminoglycan release into the conditioned medium was signif-
icantly inhibited bywild-typeTIMP-3 at 100 nMbut not at 10 or
50 nM (Fig. 7A). Comparable inhibition was seen using the
DMMB dye-binding assay and immunoblotting with the anti-
AGEG neoepitope antibody, which detects ADAMTS-medi-
ated cleavage at the TAQE17712A1772GEG site in the aggrecan
C-terminal chondroitin sulfate-rich region. K26A/K45A and
K42A/K110A inhibited aggrecan degradation at lower concen-
trations, with significant inhibition observed at 10, 50, and 100
nM concentrations of each mutant (Fig. 7, B and C). No cell
toxicity was observed for any of the treatment conditions (not
shown).
To evaluate the time course of protection, explants were cul-
tured with 100 nM TIMP-3, TIMP-3 K26A/K45A, or TIMP-3
FIGURE 3. Mutation of pairs of lysine residues further increases the half-life of TIMP-3 in the medium of HTB94 chondrosarcoma cells. A, HTB94
chondrosarcoma cells were incubated (0–24 h) with 1 nM FLAG-tagged wild-type TIMP-3, TIMP-3 preincubated with 1 M RAP, TIMP-3 K26A/K45A, TIMP-3
K42A/K110A, or TIMP-3 K22A/K110A inDMEMwith 0.1% FCS.Mediawere concentrated by TCAprecipitation and analyzed by immunoblottingwith anti-FLAG
M2 antibody. The loss of each mutant from the medium was calculated relative to its pixel volume at t  0 h (defined as 100%). B, data were analyzed by
densitometry using Phoretix 1D software (mean S.D. (error bars), n 3 technical replicates). Levels of TIMP-3 (black circle), TIMP-3 preincubated with 1 M
RAP (white circle), and the TIMP-3mutants K26A/K45A (red circle), K42A/K110A (blue square), and K22A/K110A (green triangle) in themedium are shown. C, the
percentageof eachTIMP-3doublemutant (meanS.D.,n3 technical replicates) remaining in themediumat24hwas calculated.After 24h, allmutantswere
present in themediumat significantly (p0.001) higher levels thanwild-type TIMP-3,with K26A/K45Aor K42A/K110A remaining in themediumat thehighest
concentration.D, HTB94 chondrosarcoma cellswere treatedwithpurifiedwild-type TIMP-3, K26A/K45A, or K42A/K110A (50or 100nM) or sodiumnitroprusside
(SNP; 10mM) for 24 h, and cell viability (mean S.D., n 3 technical replicates) was assessed using theMTS assay. Sodiumnitroprusside caused significant cell
toxicity (***, p 0.001), whereas wild-type and mutant TIMP-3 had no effect on cell viability at the concentrations tested (p 0.05).
TIMP-3Mutants Resistant to LRP1 Have Increased Half-life
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K42A/K110A for 0, 1, 2, or 3 days and then stimulatedwith IL-1
for a further 24 h. TIMP-3 inhibited aggrecan degradation after
1 and 2 days of preincubation, after which no significant pro-
tection was observed (Fig. 8). TIMP-3 K26A/K45A and K42A/
K110A, however, significantly protected cartilage against an
IL-1 challenge even after 3 days of preincubation on the
explants (Fig. 8). K26A/K45A inhibited cartilage degradation
significantly more effectively than K42A/K110A after 2 and 3
days of preincubation.
Discussion
The phenotype of Timp3-null mice demonstrates that
TIMP-3 is a central inhibitor of metalloproteinase-mediated
ECM degradation and that it serves to regulate homeostatic
tissue turnover (1–3) and limit pathological tissue remodeling
(4). We have previously demonstrated that extracellular levels
of TIMP-3 are primarily regulated at the post-translational
level, by the balance between its binding to sulfated glycosami-
noglycans of the ECMand its cellular uptake by the LRP1 endo-
cytic receptor (28). We sought to engineer a mutant of TIMP-3
with reduced affinity for LRP1 and increased half-life in the
tissue, to establish whether tissue remodeling could be modu-
lated by targeting the TIMP-3 endocytic pathway.
Following previous studies that had identified an apparent
LRP1-binding motif (13–15), we used a model of the three-
dimensional structure of TIMP-3 and identified pairs of lysine
FIGURE 4.Wild-type TIMP-3 is endocytosed into lysosomal vesicles, whereas K26A/K45A and K42A/K110A are not. HTB94 chondrosarcoma cells were
grownon gelatin-coated coverslips and incubated (2 h, 37 °C) with TIMP-3, TIMP-3 K26A/K45A, or TIMP-3 K42A/K110A (40 nM) in DMEMwith 0.1% FCS. Control
wells were incubated without TIMP-3, and LRP dependence was evaluated by incubating wells with RAP (500 nM) for 1 h before the addition of TIMP-3. After
fixing and permeabilizing the cells, TIMP-3 was detectedwithM2 anti-FLAG antibody (green), and endocytic vesicles were visualizedwith an antibody against
EEA1 (red). Nuclei were visualized by DAPI staining (blue), and the cytoskeleton was visualized by staining with phalloidin (white). Images were gathered by
confocal microscopy on a PerkinElmer Life Sciences spinning disc confocal microscope equipped with a Nikon TE-2000 CCD camera (40 objective lens).
TIMP-3Mutants Resistant to LRP1 Have Increased Half-life
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residues whose -carbon atoms are predicted to be separated
by 21 5 Å. In agreement with previous findings (13, 14), our
initial screening procedure indicated that none of the 12 lysine
residues assessed is solely responsible for LRP1 binding. Only
three of the singlemutants (K42A,K71A, andK157A) displayed
significantly longer half-lives. Of these, K71A was the most
effective, with a 3.6-fold increased half-life. However, all 10 of
the double mutants, in which pairs of lysine residues were
mutated to alanine, showed substantially longer half-lives, with
50–90% of the initial concentration remaining inmedium after
24 h. The increased half-lives of all double mutants assessed
argues against LRP1 binding being governed by a single pair of
lysine residues. This is in agreement with the recent findings of
van den Biggelaar et al. (29), who found that binding of factor
VIII to LRP1wasmediated bymultiple lysine residueswithin an
extended basic area on the surface of the ligand, leading them to
suggest an additive bindingmodel. The crystal structure of RAP
in complex with a fragment of the LDL receptor shows that 2
lysine residues of the ligand interact with adjacent acidic pock-
ets on the receptor (15). The extended binding model suggests
that this interaction is supported by the surrounding charge
landscape and that the interacting lysine residues do not act in
isolation. This model may also apply to other LRP1 ligands. For
example, double lysinemutants other than RAPK256A/K270A
also display reduced affinity for LRP1 (13, 14).
We compared the most endocytosis-resistant of the double
mutants, namely K26A/K45A and K45A/K110A, with wild-
type TIMP-3 inmore detail. Consistent with the lysine residues
being distal from the metalloproteinase-binding region of
TIMP-3, the mutants showed no change in their ability to
inhibit target prototypic metalloproteinases, aggrecanases, and
ADAM17.We assessed their biological activity using a cartilage
degradationmodel inwhich aggrecan degradation is stimulated
by treating porcine cartilage explantswith the proinflammatory
cytokine IL-1. Aggrecan degradation was inhibited by 100 nM
wild-type TIMP-3, in agreement with what has been observed
previously for the inhibitory N-terminal domain of the inhibi-
tor (6, 30). TIMP-3 K26A/K45A and K45A/K110A inhibited
aggrecan degradation more effectively, with significant inhibi-
tion observed at lower concentrations and for longer thanwild-
typeTIMP-3. This confirms our hypothesis that LRP1-resistant
mutants of TIMP-3 would have an improved ability to inhibit
metalloproteinase-mediated extracellular matrix degradation.
TIMP-3 has been reported to induce apoptosis in various cell
types (31–33), andwe explored the possibility that endocytosis-
resistant mutants of TIMP-3 may induce higher levels of apo-
ptosis due to their ability to be retained at higher levels in the
extracellular environment. We found that cell viability was not
affected by treating chondrosarcoma cells or primary chondro-
cytes with 100 nM wild-type or mutant TIMP-3 for 2 days, in
agreement with previous studies using wild-type N-TIMP-3
(6).
A characteristic feature of TIMP-3 is its ability to bind to
sulfated glycosaminoglycans of the extracellular matrix (8, 9).
Cell surface HS proteoglycans are also likely to affect the traf-
ficking of TIMP-3 in the extracellular environment. Lee et al.
(34) demonstrated that this binding was mediated by an
extended area of basic residues on the opposite side of TIMP-3
FIGURE5.Uptakeof TIMP-3 is LRP1-dependent. LRP1wild-type (PEA10;A) and LRP1null (PEA13;B) cellswere incubated (0–8h)with FLAG-taggedwild-type
TIMP-3, TIMP-3 K26A/K45A, or K42A/K110A (1 nM) in DMEM with 0.1% FCS. Media were concentrated by TCA precipitation and analyzed by immunoblotting
with anti-FLAGM2 antibody. The loss of each protein from the mediumwas calculated relative to its pixel volume at t 0 h (defined as 100%). Immunoblots
show representative experiments, and graphs show analysis of three technical replicates (mean S.D. (error bars)).
TIMP-3Mutants Resistant to LRP1 Have Increased Half-life
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to its inhibitory ridge. The lysine residues in K26A/K45A and
K42A/K110A are situated within or adjacent to this basic area
(Fig. 9). The mutants retain detectable, albeit reduced, binding
to heparin and heparan sulfate, consistent with the require-
ment to mutate 6 basic residues to ablate ECM binding (34).
Binding of TIMP-3 to sulfated glycosaminoglycans both
inhibits its clearance by LRP1 and increases its affinity for gly-
cosaminoglycans-binding target enzymes through formation of
high affinity TIMP-3metalloproteinaseglycosaminoglycan
complexes (28). In the context of osteoarthritis, both the colla-
genase MMP-13 and the aggrecanases ADAMTS-4 and
ADAMTS-5 are susceptible to such ECM-mediated increase in
TIMP-3 potency (10). Comparing the affinities of the mutants
for sulfated glycosaminoglycans and LRP1 gives insight into the
relative importance of matrix binding and LRP1-mediated
clearance for the biological activity of TIMP-3. TIMP-3 K42A/
K110A had greater resistance to endocytosis and lower affinity
for LRP1 than was observed for K26A/K45A but also had lower
affinity for sulfated glycosaminoglycans and did not display
increased affinity for ADAMTS-5 in the presence of heparin.
Both mutants protected cartilage more effectively than wild-
type TIMP-3, but K26A/K45A showed greater inhibition after
extended incubation on cartilage. This suggests that interaction
withmatrix glycosaminoglyans supports the protective effect of
TIMP-3 in the complex, dynamic tissue environment.
Extracellular levels of other LRP1 ligands may be similarly
regulated by the equilibrium between matrix binding and
FIGURE6.Characterizationof TIMP-3K26A/K45AandK42A/K110Abindingproperties.A, bindingofwild-type TIMP-3 (black circle), K26A/K45A (red circle),
andK42A/K110A (blue square) to LRP1wasanalyzedbyELISA.Medium-bindingELISAplateswere coatedwith LRP1 (5nM)overnight and incubatedwith0.4–50
nMwild-type or mutant TIMP-3, either alone (closed symbols) or preincubated with heparin (open symbols; 150g/ml, 1 h, 37 °C). Bound protein was detected
using an M2 anti-FLAG primary antibody and anti-mouse-HRP secondary antibody. Hydrolysis of 3,3,5,5-tetramethylbenzidine substrate was analyzed by
measuring absorbance at 450 nm (mean S.D. (error bars), n 3 technical replicates). B, binding of wild-type TIMP-3 (black circle), K26A/K45A (red circle), and
K42A/K110A (blue square) to heparin was analyzed by ELISA. Glycosaminoglycan-binding ELISA plates were coated with heparin (10 g/ml) overnight and
incubated with 0.4–25 nM wild-type or mutant TIMP-3. Bound protein was detected as in A (mean S.D., n 3 technical replicates). C, binding of wild-type
TIMP-3 (black circle), K26A/K45A (red circle), and K42A/K110A (blue square) to heparan sulfate was analyzed by ELISA. Glycosaminoglycan-binding ELISA plates
were coatedwithheparan sulfate (10g/ml) overnight and incubatedwith0.4–25nMwild-typeormutant TIMP-3. Boundproteinwasdetectedas inA (mean
S.D., n 3 technical replicates). D, ADAMTS-5 (0.5 nM) was incubated with wild-type TIMP-3 (0.5–10 nM) without (black circle) or with heparin (100 nM, white
circle) for 1h at 37 °C, and residual enzymeactivitywasquantified (18h, 37 °C,mean S.D.,n3 technical replicates). E, ADAMTS-5 (0.5 nM)was incubatedwith
K26A/K45A (0.5–10 nM) without (black circle) or with heparin (100 nM, white circle) for 1 h at 37 °C, and residual enzyme activity was quantified (18 h, 37 °C,
mean S.D., n 3 technical replicates). F, ADAMTS-5 (0.5 nM)was incubatedwith K42A/K110A (0.5–10 nM)without (blue square) orwith heparin (100 nM,white
square) for 1 h at 37 °C, and residual enzyme activity was quantified (18 h, 37 °C, mean S.D., n 3 technical replicates).
TABLE 2
Affinity ofwild-type andmutant TIMP-3 for prototypic targetmetallo-
proteinases
Wild-type TIMP-3 and its mutants K26A/K45A and K42A/K110A (0.25–25 nM)
were incubated with target metalloproteinases (1 h, 37 °C), and residual activity
against synthetic fluorescent substrates was determined. Equilibrium velocities
were used to calculate the apparent inhibition constant Ki(app) (mean  S.D.,
n 3–5 technical replicates) using the tight binding equation. ND, too low to be
determined.
Ki(app)
Wild-type
TIMP-3
TIMP-3
K26A/K45A
TIMP-3
K42A/K110A
nM
MMP-1C 1.20 0.49 0.52 0.33 0.60 0.30
MMP-2C 0.60 0.32 0.63 0.49 0.60 0.53
MMP-3C 1.20 0.47 0.92 0.19 1.40 0.09
ADAMTS-4 0.19 0.01 0.12 0.04 0.24 0.07
ADAMTS-5 1.27 0.46 0.95 0.55 1.12 0.94
ADAMTS-5	 heparin ND ND 1.20 0.42
ADAM17 3.54 1.19 3.78 1.79 2.34 1.40
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LRP1-mediated uptake that we have observed for TIMP-3. For
example, heparin inhibits LRP1 binding of factor IXa (35), apo-
lipoprotein A-V (36), C4b-binding protein (37), and PAI-1 (38,
39), and several other LRP1 ligands (e.g. ADAMTS-4,
ADAMTS-5, MMP-13, TGF, CTGF, midkine, thrombospon-
din) are known to bind to heparin or heparan sulfate (40–46).
The bioavailability of these proteins is thus likely to be modu-
lated by factors governing their retention on heparan sulfate
proteoglycans, such as the pattern and degree of sulfation on
heparan sulfate. Matrix turnover may thus be regulated by the
dynamic alterations in sulfation that are observed, for example,
with age (47) and inflammation (48).
Timp3-null mice also exhibit increased sensitivity to TNF-
mediated pathologies, such as impaired liver regeneration (49),
indicating the importance of TIMP-3 as a regulator of
ADAM17, which sheds membrane-bound TNF to release the
soluble form of this pleiotropic proinflammatory cytokine. The
effects of K26A/K45A and K42A/K110A on TNF-dependent
chronic inflammatory conditions would be of interest. Aggre-
canase-selective and ADAM17-selective TIMP-3mutants with
increased half-life could be created by combining the LRP1-
resistant mutants described here with previously characterized
selective TIMP-3 mutants (30, 50). These mutants or small
molecule inhibitors of TIMP-3 endocytosis may be of use in
osteoarthritis as well as in other pathological conditions char-
acterized by excess, dysregulated metalloproteinase activity,
such as cancer and chronic diabetic wounds.
Experimental Procedures
Materials—DMEM, penicillin/streptomycin, HEPES, and
trypsin-EDTA were from Lonza (Slough, UK). Sodium chlo-
rate, porcine mucosal heparin, amphotericin B, and chondroi-
tin-4-sulfatewere fromSigma-Aldrich (Dorset, UK).Hygromy-
cin Bwas fromCalbiochem (Nottingham,UK). Heparan sulfate
was from Iduron (Cheshire, UK). FCS was fromGibco (Paisley,
UK). Lipofectamine 2000 transfection reagent was from Invit-
rogen (Paisley, UK).
Construction of TIMP-3 Model—ICM-Pro fromMolsoft was
used to create a homology model of TIMP-3 based on its
sequence similarity with TIMP-2 (22). Global pairwise
sequence alignment between the homologues was used as the
basis for initial structural superposition followed by con-
strained optimization of side chains and loops. The distance
between -carbon residues of pairs of lysine residues was mea-
sured using PyMOL.
Generation of TIMP-3Mutants—TIMP-3mutants were gen-
erated using the QuikChange II XL site-directed mutagenesis
kit (Agilent Technologies, Cheshire, UK), with C-terminally
FLAG-tagged wild-type TIMP-3 in pCEP4mammalian expres-
sion vector used as the template (24). All mutants generated are
shown in Table 1. Primers for generation of K22Awere 5-TCC
GAC ATC GTG ATC CGG GCC GCG GTG GTG GGG AAG
FIGURE 7. Effect of TIMP-3 mutants on aggrecan degradation in porcine
cartilage explants. A–C, porcine articular cartilage explants were cultured in
cartilage medium with 0.1% FCS (250 l) and/or IL-1 (10 ng/ml) and/or wild-
type TIMP-3 (A), K26A/K45A (B), or K42A/K110A (C) (0, 10, 50, or 100 nM). After
2 days, conditioned media were harvested, and aggrecan degradation was
analyzed by immunoblotting with the anti-1772AGEG neoepitope antibody
(representativeblot shown) andDMMBassay (graph showinggof aggrecan
released, mean S.D. (error bars), n 3 biological replicates). *, p 0.05; **,
p 0.01; ***, p 0.001 compared with IL-1-stimulated explants. The vertical
line indicates where a single lane has been cropped from the images.
FIGURE 8. TIMP-3 K26A/K45A and K42A/K110A protect cartilage for lon-
ger than the wild-type inhibitor. Porcine articular cartilage explants were
cultured in cartilagemediumwith 0.1% FCS (250l) and/orwild-type TIMP-3,
K26A/K45A, or K42A/K110A (100 nM). After 0, 1, 2, or 3 days, explants were
stimulated with IL-1 (10 ng/ml) for 24 h, and aggrecan degradation was ana-
lyzed by a DMMB assay (mean S.D. (error bars), n 3 biological replicates).
*, p 0.05; **, p 0.01; ***, p 0.001.
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AAG CTG-3 (forward) and 3-AGG CTG TAG CAC TAG
GCC CGG CGC CAC CAC CCC TTC TTC GAC-5 (reverse);
primers for K26A were 5-CGG GCC AAG GTG GTG GGG
GCG AAG CTGGTA AAGGAGGGG CCC-3 (forward) and
3-GCCCGGTTCCACCACCCCCGCTTCGACCATTTC
CTC CCC GGG-5 (reverse); primers for K27A were 5-CGG
GCC AAGGTGGTGGGGAAGGCG CTGGTA AAGGAC
GGG CCC-3 (forward) and 3-GCC CGG TTC CAC CAC
CCC TTC CGC GAC CAT TTC CTG CCC GGG-5 (reverse);
primers for K30A were 5-GTC GTG GGG AAG AAG CTG
GTAGCGGAGGGGCCCTTCGGCACGCTG-3 (forward)
and 3-CAG CAC CCC TTC TTC GAC CAT CGC CTC CCC
GGG AAG CCG TGC GAC-5 (reverse); primers for K42A
were 5-GGC ACG CTG GTC TAC ACC ATC ACG CAG
ATGAAGATGTACCAGGC-3 (forward) and 3-CCGTGC
GAC CAG ATG TGG TAG CGC GTC TAC TTC TAC ATG
GCT CCG-5 (reverse); primers for K45A were 5-ACG CTG
GTC TAC ACC ATC AAG CAG ATG GCG ATG TAC CGA
GGC TTC ACC-3 (forward) and 3-GAC CAG ATG TGG
TAG TTC GTC TGC CGC TAC ATG GCT CCG AAG
TGG-5 (reverse); primers for K52A were 5-AAG ATG TAC
CGA GGC TTC ACC GCG ATG CCC CAT GTG CAG TAC
ATC CAC-3 (forward) and 3-TTC TAC ATG GCT CCG
AAG TGG CGC TAC GGG GTA CAC GTC ATG TAG
GTG-5 (reverse); primers for K71A were 5-GCT TCC GAG
AGT CTC TGT GGC CTT GCG CTG GAG GTC AAC AAG
TAC CAG-3 (forward) and 3-CGA AGG CTC TCA GAG
ACA CCG GAA CGC GAC CTC CAG TTG TTC ATG
CTC-5 (reverse); primers for K76A were 5-GGC CTT AAG
CTG GAG GTC AAC GCG TAC CAG TAC CTG CTG ACA
GGT CGC-3 (forward) and 3-CCG GAA TTC GAC CTC
CAG TTG CGC ATG GTC ATG GAC GAC TGT CCA
GCG-5 (reverse); primers for K89A were 5-GGT CGC GTC
TAT GAT GGC GCG ATG TAC ACG GGG CTG TGC-3
(forward) and 3-CCA GCG CAG ATA CTA CCG CGC TAC
ATG TGC CCC GAC ACG-5 (reverse); primers for K110A
were 5-CAG CTC ACC CTC TCC CAG CGC GCG GGG
CTG AAC TAT CGG TATC-3 (forward) and 3-GTC GAG
TGG GAG AGG GTC GCG CGC CCC GAC TTG ATA GCC
ATAG-5 (reverse); and primers for K157A were 5-GGT TAC
CCT GGC TAC CAG TCC GCG CAC TAC GCC TGC ATC
CGG-3 (forward) and 3-CCA ATG GGA CCG ATG GTC
AGGCGCGTGATGCGGACGTAGGCC-5 (reverse). PCR
conditions were as per the manufacturer’s instructions, except
that 100 ng of templatewas used per reaction, and the extension
time per cycle was increased to 150 s/kb (1435 s). PCR products
were digested with DpnI and transformed into E. coli XL10-
Gold ultracompetent bacteria by heat shock, and cells were
plated on carbenicillin agar. Candidate colonies were screened
by restriction digestion with XhoI and subsequent DNA
sequencing (Eurofins MWGOperon, Ebersberg, Germany).
Cell Culture—HEK-293-EBNAandHTB94 human chondro-
sarcoma cells (both from ATCC, Manassas, VA) were main-
tained in DMEM with 10% FCS, 100 units/ml penicillin, and
100 units/ml streptomycin at 37 °C in 5% CO2.
Screening of Mutants—For initial screening of the mutants,
we evaluated their resistance to clearance from conditioned
medium.
HEK-293-EBNA cells were transiently transfected with
pCEP4 expression plasmids encoding wild-type or mutant
TIMP-3 using Lipofectamine 2000 and incubated in serum-free
DMEMwith 30mMNaClO3 for 2 days (24). Conditionedmedia
(500 ml) were harvested and dialyzed against TBS (2  1 liter,
18 h, 4 °C). The concentration of eachmutant was standardized
to 1 nM by comparison with purified recombinant TIMP-3 of
known, titrated concentration by immunoblottingwith an anti-
FLAGM2 antibody (F1804-5MG, Sigma-Aldrich, Dorset, UK).
We evaluated clearance of the TIMP-3 mutants from the
medium of HTB94 chondrosarcoma cells. HTB94 cells were
seeded overnight (8  105 cells/well of a 12-well plate) in
DMEM with 10% FCS. Wells were washed three times in
serum-free DMEM and incubated in DMEM with 0.1% FCS
and the dialyzed HEK-293-EBNA conditioned medium con-
taining wild-type or mutant TIMP-3 (1 nM). Samples were har-
vested at various time points (0–24 h), and proteins were con-
centrated by the addition of TCA to a final concentration of 5%
(18 h, 4 °C) (51) and subsequent centrifugation (13,000 rpm, 10
min, 4 °C). Pellets were resuspended in SDS-PAGE sample
buffer and analyzed by immunoblotting with anti-FLAG M2
antibody. Pixel volumes within the linear range of detection
were quantified using Phoretix 1D densitometry software
(TotalLab, Newcastle-upon-Tyne, UK), and half-life or per-
centage ofwild-type ormutantTIMP-3 remaining in themedium
(mean S.D.) was calculated relative to their own pixel volume at
t 0 h (defined as 100%). Half-lives were calculated by fitting the
data to a first order exponential decay model using Prism
(GraphPad Software, Inc., La Jolla, CA). Data from three indepen-
dent experiments were analyzed for statistical significance using
FIGURE 9.Model of endocytosis-resistant mutants of TIMP-3. TIMP-3 contains an extended region of basic residues, depicted as the blue area calculated with
PyMOLqualitative vacuumelectrostatics. This region includes Lys-26/Lys-45 (A) and Lys-42/Lys-110 (B), whosemutation to alanine reduced TIMP-3 binding to LRP1.
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one-way ANOVA with Dunnet’s post hoc test for multiple com-
parisons with Prism (GraphPad Software).
Uptake of wild-type and mutant TIMP-3 by LRP1 wild-type
(PEA10) and LRP1-null (PEA13) cells was compared. Cells
were seeded overnight at 3  105 cells/well of a 12-well plate.
Wells were washed three times in serum-free DMEMand incu-
bated with purified wild-type or mutant TIMP-3 (1 nM) in
DMEM with 0.1% FCS. Conditioned media were analyzed by
immunoblotting as described above for HTB94.
Purification of Wild-type and Mutant TIMP-3—Wild-type
and mutant TIMP-3 were expressed and purified by modifica-
tion of the protocol described previously (24). HEK-293-EBNA
cells were stably transfected with pCEP4 expression plasmids
encoding wild-type or mutant TIMP-3 and selected using
hygromycin B (100 g/ml for TIMP-3 mutants, 800 g/ml for
wild-type TIMP-3). Stable cell lines were treated with serum-
free DMEM containing 30 mM NaClO3 for 48 h. Conditioned
medium was harvested, centrifuged to remove cell debris, and
passed over an anti-FLAG M2 affinity resin (Sigma-Aldrich)
equilibrated in DMEM. The resin was washed in DMEM con-
taining 1 M NaCl and then extensively washed in DMEM.
Bound wild-type or mutant TIMP-3 was eluted with FLAG
peptide (200 g/ml) in DMEM and stored at
80 °C in LoBind
microcentrifuge tubes (Eppendorf, Stevenage, UK). The purity
of isolated TIMPswas confirmed by silver staining (silver stain-
ing kit, Pierce), and their active concentrations were deter-
mined by titration against a known concentration of MMP-1.
Confocal Microscopy Imaging of Endocytosis—HTB94 cells
(104 cells) were plated on gelatin-coated coverslips in 12-well
plates.Wells were washed in serum-free DMEMand incubated
for 2 h at 37 °C with TIMP-3, TIMP-3 K26A/K45A, or TIMP-3
K42A/K110A (40 nM) in DMEM with 0.1% FCS. Control wells
were incubated without TIMP-3, and LRP dependence was
evaluated by incubating wells with RAP (500 nM) for 1 h before
the addition of TIMP-3. Wells were washed three times in PBS
after each of the steps hereafter. Cells were fixed with 3% para-
formaldehyde plus PBS (10 min, 25 °C), blocked with 5% goat
serum plus 3% BSA plus PBS (1 h, 25 °C), and permeabilized in
0.1% Triton X-100 plus PBS (15 min, 25 °C). Cells were stained
with mouse anti-FLAG M2 (5 g/ml F1804-5MG, Sigma-Al-
drich) and rabbit anti-EEA1 and 0.5 g/ml ab2900 (AbCam,
Cambridge,UK) antibodies in block (3 h, 25 °C). Boundprimary
antibodies were detected with anti-mouse DyLight 679 (Ther-
moFisher, Waltham, MA) and anti-rabbit Alexa Fluor 568
(Molecular Probes, Inc., Eugene, OR) in block (1 h, 25 °C). Nuclei
were visualized (1 h, 25 °C) with DAPI (ThermoFisher), and actin
wasvisualizedwithphalloidinAlexaFluor488 (MolecularProbes).
Cells were mounted in ProLong Diamond antifade mountant
(ThermoFisher) and analyzed on a PerkinElmer Life Sciences
spinning disc confocal microscope equipped with a Nikon
TE-2000 CCD camera (40 objective lens).
Cell Viability Assays—Cell viability of HTB94 chondrosar-
coma cells or porcine cartilage explantswas assessed after treat-
ment with wild-type or mutant TIMP-3 (0–100 nM) with or
without IL-1 (10 ng/ml) for 24 h in DMEM containing 0.1%
FCS. Sodium nitroprusside (10 mM) was used as a control to
induce cell death. Media were replaced with fresh DMEMwith
0.1% FCS and MTS reagent (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazoli-
um; Promega, Southampton, UK) according to the manufactu-
rer’s instructions. Absorbance at 490 nmwasmeasured after 45
min using a FLUOstar OMEGA microplate reader (BMG
Labtech, Aylesbury, UK). Data (mean  S.D., n  3 technical
repeats)were analyzed for statistical significance using one-way
ANOVAwith Dunnet’s post hoc test formultiple comparisons.
Recombinant Proteins—The catalytic domains of MMP-1
(MMP-1C), MMP-2 (MMP-2C), and MMP-3 (MMP-3C)
were prepared as described previously (24, 52, 53). ADAMTS-4
lacking the C-terminal spacer domain and ADAMTS-5 lacking
the C-terminal thrombospondin domain were expressed and
purified as described previously (54, 55). ADAM17 ectodomain
was a gift from Professor Gillian Murphy (University of Cam-
bridge). RAP was prepared as described previously (56).
Determination of Apparent Inhibition Constants Ki(app) of
Wild-type and Mutant TIMP-3—The affinity of wild-type and
mutant TIMP-3 for prototypic target metalloproteinases was
determined under equilibrium conditions, as described previ-
ously (27). The assay buffer contained 50 mM TrisHCl, pH 7.5,
150mMNaCl, 10mMCalCl2, 0.05% Brij 35, 0.02%NaN3, except
for ADAM17, which was assayed in 50mMTrisHCl, pH 7.5, 25
mM NaCl, 10 mM CalCl2, 0.05% Brij 35, 0.02% NaN3. Metallo-
proteinases (0.5–1 nM) were preincubated with wild-type or
mutant TIMP-3 (0.25–25 nM)with or without heparin (100 nM)
for 1 h at 37 °C, and residual activity was determined (20min to
18 h) using fluorescence-quenched substrates (from Bachem
(Bubendorf, Switzerland) unless otherwise indicated). MMP-
1C and MMP-2C were assayed using Mca-Pro-Leu-Gly-
Leu-Dap(Dnp)-Ala-Arg-NH2 (1.5 M) (57), MMP-3C using
Mca-Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met-Lys(Dnp)-NH2
(1.5 M) (58), ADAMTS-4 using carboxyfluorescein-Ala-Glu-
Leu-Asn-Gly-Arg-Pro-Ile-Ser-Ile-Ala-Lys-N,N,N,N-tetram-
ethyl-6-carboxyrhodamine (0.5 M) (59), ADAMTS-5 using
ortho-aminobenzoyl-Thr-Glu-Ser-Glu-Ser-Arg-Gly-Ala-Ile-
Tyr-(N-3-[2,4-dinitrophenyl]-L-2,3-diamiopropionyl)-Lys-
Lys-NH2 (20 M) (60), and ADAM17 using Abz-Leu-Ala-
Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Dpa (20 M; Calbiochem,
Watford, UK) (61). End point fluorescence wasmeasured using
a Gemini microplate spectrofluorimeter (Molecular Devices,
Wokingham, UK) and the apparent inhibition constantKi(app)
(mean  S.D., n  3 technical replicates) determined from
steady-state velocities by fitting the data to the tight binding
equation (62) using Prism (GraphPad Software).
Binding to LRP1—LRP1 (5 nM; BioMac, Leipzig, Germany)
was coated (overnight, 4 °C) onto medium-binding ELISA
plates (Greiner Bio-One, Stonehouse, UK) in 20 mM HEPES,
150mMNaCl, 5mMCaCl2, 0.05%Tween 20, pH 7.4.Wells were
blocked with 10% BSA in TNC buffer (50 mM TrisHCl, pH 7.5,
150 mMNaCl, 10 mM CaCl2, 0.05% Brij 35). Wells were washed
in TNC buffer containing 0.1%Tween 20 after this and every sub-
sequent step. Purified wild-type or mutant TIMP-3 (0.4–50 nM),
either alone or preincubated with heparin (150g/ml, 1 h, 37 °C),
was applied towells inTNCbuffer containing 5%BSA (3h, 25 °C).
Binding was detected with anti-FLAG M2 primary antibody and
anti-mouse-HRP-conjugated secondary antibody in the same
buffer. 3,3,5,5-tetramethylbenzidine (Becton Dickinson, Swin-
don, UK) substrate was added, the reaction was stopped when
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appropriate by the addition of 2 N H2SO4, and absorbance at 450
nm was measured using a FLUOstar OMEGAmicroplate reader
(BMG Labtech). Data (mean  S.D., n  3 technical replicates)
were analyzed using Prism (GraphPad Software).
Binding to Heparin and Heparan Sulfate—Heparin and
heparan sulfate (10 g/ml) were coated (overnight, 25 °C) onto
glyosaminoglycan-binding ELISA plates (BD Biosciences,
Oxford, UK) in PBS, and wells were blocked with 0.2% gelatin in
PBS(1h,37 °C).Wellswerewashed inPBScontaining0.1%Tween
20 after this and every subsequent step. Purified wild-type or
mutant TIMP-3 (0.2–25 nM) in blocking solution was applied to
wells (3 h, 37 °C), and binding was detected with anti-FLAG M2
primary antibody and anti-mouse-HRP-conjugated secondary
antibody. 3,3,5,5-Tetramethylbenzidine (Becton Dickinson)
substrate was added, the reaction was stopped when appropriate
by the addition of 2 NH2SO4, and absorbance at 450 nmwasmea-
sured using a FLUOstar OMEGA microplate reader (BMG
Labtech). Data (mean  S.D., n  3 technical replicates) were
analyzed using Prism (GraphPad Software).
Cartilage Explant Cultures—Porcine articular cartilage
explants were dissected from metacarpophalangeal joints of
3–9-month-old pigs within 24 h of slaughter using a biopsy
punch to ensure uniformity of size. Explants were rested for 2
days in cartilagemedium (DMEMcontaining 100units/ml pen-
icillin, 100 units/ml streptomycin, 2 mg/ml amphotericin B, 10
mMHEPES)with 10%FCS (500l ofmedium, 48-well plates) at
37 °C in 5% CO2. Cartilage explants were then washed into car-
tilagemedium (250l) with 0.1% FCS and treated with IL-1 (10
ng/ml, PeproTech, London, UK) and/or wild-type or mutant
TIMP-3 (0–100 nM) for 0–72 h. IL-1 treatment stimulated cat-
abolic pathways leading to degradation of the cartilage ECM by
TIMP-3 target enzymes and release of degraded aggrecan frag-
ments from the cartilage into the conditioned medium (63).
Conditioned media were harvested, and aggrecan degradation
was quantified (3 technical replicates per condition) using the
dimethylmethylene blue (DMMB) dye-binding assay that
quantifies chondroitin sulfate-rich fragments of aggrecan
released into themedium though the action of ADAMTSs (64).
Data from experiments with three biological replicates were
analyzed for significance using one-way ANOVA with Dun-
net’s post hoc test for multiple comparisons.
Aggrecan fragments released into themediumwere also ana-
lyzed by immunoblotting (2 technical replicates per condition)
using a neoepitope antibody that recognizes the new N termi-
nus generated by ADAMTS-dependent cleavage of aggrecan at
the TAQE17712A1772GEG site (10).
Author Contributions—L. T. and H. N. conceived the study, coordi-
nated the work, and wrote the paper. D. D. generated the TIMP-3
model, R. V. designed the mutants, D. K. S. provided the LRP1-null
cells, and C. M. D. generated and analyzed the mutants.
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